Phase 1 clinical trial of autologous T-cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer (OVCA).

Authors: Robert Michael Wenham, Marco L. Davila, Daniel Abate-Daga, Melissa McGettigan, Xuefeng Wang, Theresa A. Boyle, Pamela D. Garzone, Amit Kumar, Denise Dorman, Richard Koya, Jose Conejo-Garcia

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps2682

Source: Full article

---

Abstract

TPS2682